Reed Elsevier's new chairman takes a stake
A round-up of the biggest director deals today so far.
Reed Elsevier's new chairman Anthony Habgood has signalled his commitment to the specialist publisher with the purchase of £218,000 in shares.
He paid 436p a time for 50,000, his first stake in the firm, whose stable of publications includes Farmers' Weekly and New Scientist.
His purchase comes after a sharp drop in Reed's share price following the announcement of a placing to raise more than £800m to help it pay debts.
Subscribe to MoneyWeek
Subscribe to MoneyWeek today and get your first six magazine issues absolutely FREE

Sign up to Money Morning
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
Don't miss the latest investment and personal finances news, market analysis, plus money-saving tips with our free twice-daily newsletter
The firm also revealed a rise in revenues and adjusted earnings. Revenues in half year to June 2009 climbed 25% to £3.06bn, with adjusted earnings per share rising by 21% to 24.5p. Profit before tax fell to £188m from £393m.
The firm said professional information businesses were relatively robust, while advertising and promotion markets were significantly impacted by global recession.
Top Director Buys
Value: £218,000
Value: $64,528
Value: £19,819
Top Director Sells
Value: £394,056
Value: £127,000
Value: £79,272
Value: £55,278
Value: £12,544
Sign up for MoneyWeek's newsletters
Get the latest financial news, insights and expert analysis from our award-winning MoneyWeek team, to help you understand what really matters when it comes to your finances.
-
UK-US trade deal announced: US cuts tariffs on UK car imports to 10%
Keir Starmer and Donald Trump have announced a UK-US trade deal, but the US president has refused to lift baseline tariffs on most UK goods. What does it mean for the UK?
-
How to use mid-caps to diversify from the US
Medium sized companies are overlooked by investors but could offer an attractive ‘sweet spot’. We consider the case for mid-caps amid market volatility.